NDA 019219 · Allergan
Betagan
Levobunolol Hydrochloride · Ophthalmic
NovelLast checked: Nov 20, 2026Latest source record: Dec 22, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
Dec 19, 1985
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 1985 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
- BETAGAN · LEVOBUNOLOL HYDROCHLORIDE 0.5% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Levobunolol" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Superior oblique myokymia.
Zhang M, Gilbert A, Hunter DG · Surv Ophthalmol 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- The effect of levobunolol on aqueous humor dynamics.
Yablonski ME, Novack GD, Burke PJ, et al. · Exp Eye Res 1987 · Clinical Trial, Randomized Controlled Trial
- Comparison of ophthalmic beta-blocking agents.
Lesar TS · Clin Pharm 1987 · Clinical Trial, Comparative Study
- A multicenter evaluation of levobunolol (Vistagan) in Germany.
Novack GD, Kelley EP, Lue JC · Ophthalmologica 1988 · Clinical Trial, Multicenter Study
- Once-daily versus twice-daily levobunolol (0.5%) therapy. A crossover study.
Derick RJ, Robin AL, Tielsch J, et al. · Ophthalmology 1992 · Clinical Trial, Comparative Study
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.